Biogen Angles For Facet With 2nd Hostile Bid
Biogen Idec Inc. has made a "best and final" tender offer to purchase Facet Biotech Corp., upping its ante from $14.50 to $17.50 a share and urging Facet's stockholders to send...To view the full article, register now.
Already a subscriber? Click here to view full article